Drugs / DS-1971
last change Feb 2017 re-read 2 minutes ago

DS-1971

also known as DS 1971a · CPD 6O

Small molecule

Developed for
neuropathy, painful
Investigated by
Daiichi Sankyo

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT02564861 Sep → Dec 2015 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02473627 May → Jul 2015 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02266940 Nov 2014 → Jan 2015 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02261376 Sep → Nov 2014 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02190058 Jul → Nov 2014 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02107885 Mar → Jul 2014 Daiichi Sankyo Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02673866 Feb 2016 → Jan 2017 diabetes mellitus, neuropathy, painful Daiichi Sankyo Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as DS-1971 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02107885
Known as CPD 6O ChEMBL registry synonym — accepted as the source's own label CHEMBL4633566
Known as DS 1971a DS 1971a is supplied as a powder or crystals and will be given as an oral suspension” NCT02564861
6

NCT02673866

NCT02190058

NCT02564861

NCT02473627

NCT02266940

NCT02261376

Modality Small molecule CHEMBL4633566
Route Oral “following oral administration” NCT02190058